ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SOC INSTI-based ART

Its studies are mostly in HIV Infections, led by GlaxoSmithKline.

Furthest: phase 1, since Jun 26, 20251 company-led study, 1 open or runningNext primary completion: Jan 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 1since Jun 26, 2025Jun 26, 2025Jan 22, 2027phase 1 · NCT07053384

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2025First study: phase 1 study in HIV InfectionsFirst studyNCT07053384 · 107 enrolled · United States, Belgium, Denmark and more

Ahead

  1. Jan 22, 2027Primary completion: phase 1 study in HIV InfectionsNCT07053384

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07053384HIV Infections · United States, Belgium, Denmark and more1Active, not recruitingJan 22, 2027107

How it is read

Names in the registry

  • “SOC INSTI-based ART”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.